Hikma Pharmaceuticals Plc Notification of major interest in shares (7547C)
January 21 2015 - 6:19AM
UK Regulatory
TIDMHIK
RNS Number : 7547C
Hikma Pharmaceuticals Plc
21 January 2015
Notification of major interests in shares
LONDON, 21 January 2015 - Hikma Pharmaceuticals PLC ("Hikma")
(LSE: HIK) (DIFX: HIK), the fast growing multinational
pharmaceuticals group, announces as follows:
1 Identity of the issuer or the underlying Hikma Pharmaceuticals PLC
issuer of existing shares to which the
voting rights are attached
2 Reason for the notification
An acquisition or disposal of voting rights Yes
--------------------------------------------------------- ----
An acquisition or disposal of financial instruments No
which may result in the acquisition of shares already
issues to which voting rights are attached
--------------------------------------------------------- ----
An event changing the breakdown of voting rights No
--------------------------------------------------------- ----
Other (please specify): Compliance with the Transparency No
Directive
--------------------------------------------------------- ----
3 Full name of the person subject to the FMR LLC
notification obligation
4 Full name of shareholders See attached schedule
--------------------------------------------------------------- --------------------------------------
5 Date of the Transaction (and date on 19 January 2015
which the threshold crossed is reached
differently)
--------------------------------------------------------------- --------------------------------------
6 Date on which the issuer notified 20 January 2015
--------------------------------------------------------------- --------------------------------------
7 Threshold that is crossed 5%
--------------------------------------------------------------- --------------------------------------
8 Notified details See A, B & C below
----- --------------------------------------------------------------- --------------------------------------
A. Voting rights attached to shares
Class type Situation previous Resulting situation after the triggering
of shares to the triggering transaction
(if possible transaction
using the
ISIN code)
------------------------ ------------------------------------------------------------------
Number Number Number of shares Number of voting % of voting
of shares of voting rights rights
rights
----------- ----------- ------------------- --------------------- ----------------------
Direct Indirect Direct Indirect Direct Indirect
----------- ----------- ------- ---------- --------- ---------- ------- -------------
Ordinary
Shares (0.10
GBP)
GB00B0LCW083 10,043,409 10,043,409 - 9,893,409 - 9,893,409 - 4.98
----------- ----------- ------- ---------- --------- ---------- ------- -------------
B. Qualifying Financial instruments
Resulting situation after the triggering transaction
Type of financial Expiration Exercise/Conversion Number of voting % of voting rights
instrument Date Period/Date rights that may
be acquired if
the instrument
if exercised/converted
----------- -------------------- ------------------------ -------------------
- - - - -
----------- -------------------- ------------------------ -------------------
C: Financial Instruments with similar economic effect to Qualifying
Financial Instruments
Resulting situation after the triggering transaction
Type of Exercise Expiration Exercise/Conversion Number of voting % of voting rights
financial Price Date Period/Date rights instrument
instrument refers to
--------- ----------- -------------------- ------------------- ---------------------
Nominal Delta
--------- ----------- -------------------- ------------------- ----------- --------
- - - - - - -
--------- ----------- -------------------- ------------------- ----------- --------
Total A+B+C
Number of Voting rights % of voting rights
-------------------
9,893,409 4.99%
-------------------
9 Chain of controlled undertakings through which the voting rights
and/or the financial instruments are effectively held, if applicable
Proxy Voting
10 Name of Custodian Day to Day IM Total
the proxy BANK OF NEW YORK BRUSSELS PGALLC-PYRAMIS GLOBAL ADVISORS,
holder (C) LLC 8,051
PGALLC-PYRAMIS GLOBAL ADVISORS,
BANK OF NEW YORK MELLON LLC 156,712
BROWN BROTHERS HARRIMAN FMR UK-FIDELITY MANAGEMENT &
AND CO RESEARCH (U.K.) INC. 25,001
PGALLC-PYRAMIS GLOBAL ADVISORS,
LLC 68,425
PGATC-PYRAMIS GLOBAL ADVISORS
TRUST COMPANY 822,664
PGALLC-PYRAMIS GLOBAL ADVISORS,
CIBC MELLON TRUST (C) LLC 19,726
CITIBANK NA, HONG KONG PGALLC-PYRAMIS GLOBAL ADVISORS,
BR (S) LLC 21,821
JP MORGAN, BOURNEMOUTH PGALLC-PYRAMIS GLOBAL ADVISORS,
(C) LLC 13,981
PGATC-PYRAMIS GLOBAL ADVISORS
TRUST COMPANY 219,471
FMR UK-FIDELITY MANAGEMENT &
JPMORGAN CHASE BANK RESEARCH (U.K.) INC. 162,476
FMRC-FMR CO., INC 3,337,724
PGALLC-PYRAMIS GLOBAL ADVISORS,
LLC 42,456
PGATC-PYRAMIS GLOBAL ADVISORS
TRUST COMPANY 83,696
PGALLC-PYRAMIS GLOBAL ADVISORS,
MELLON BANK NA (C) LLC 388,798
NATIONAL BANK TRUST PGATC-PYRAMIS GLOBAL ADVISORS
(C) TRUST COMPANY 20,223
NOMURA TRUST AND BANKING PGALLC-PYRAMIS GLOBAL ADVISORS,
(C) LLC 294
FMR UK-FIDELITY MANAGEMENT &
NORTHERN TRUST CO (C) RESEARCH (U.K.) INC. 2,865,472
PGATC-PYRAMIS GLOBAL ADVISORS
TRUST COMPANY 371,824
STATE STREET BANK AND
TR CO FMRC-FMR CO., INC 244,499
PGALLC-PYRAMIS GLOBAL ADVISORS,
LLC 453,252
PGATC-PYRAMIS GLOBAL ADVISORS
TRUST COMPANY 543,597
PGALLC-PYRAMIS GLOBAL ADVISORS,
US BANK NA (C) LLC 23,246
Grand Total 9,893,409
-------------- -----------------------------------------------------------------------------
11 Number N/A
of voting
rights
proxy holder
will cease
to hold
-------------- -----------------------------------------------------------------------------
12 Date on N/A
which proxy
holder
will cease
to hold
voting
rights
-------------- -----------------------------------------------------------------------------
13 Additional Information
14 Contact name: Peter Speirs, Company Secretary
-------------------------- --------------------------------
15 Contact telephone number: 020 7399 2772
-------------------------- --------------------------------
- ENDS -
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma's operations are conducted through three businesses:
"Branded", "Injectables" and "Generics" based primarily in the
Middle East and North Africa ("MENA") region, where it is a market
leader, the United States and Europe. In 2013, Hikma achieved
revenues of $1,365 million and profit attributable to shareholders
of $212 million.
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLBBMBTMBBTBFA
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024
